Literature DB >> 19282396

Impact of gut microbiota on intestinal and hepatic levels of phase 2 xenobiotic-metabolizing enzymes in the rat.

Walter Meinl1, Silke Sczesny, Regina Brigelius-Flohé, Michael Blaut, Hansruedi Glatt.   

Abstract

Using immunoblotting, we compared levels of phase 2 enzymes in liver, small intestine, cecum, and colon of germ-free and control rats (reassociated with rat intestinal microbiota). In addition, colonic levels were studied after association with human intestinal microbiota. The glutathione transferases (GSTs) studied, gastrointestinal glutathione peroxidase (GPX2), both epoxide hydrolases (EPHXs), and N-acetyltransferase (NAT) 1, were detected in all tissues. GPX2 and GSTP1 were highest in large bowel; the other enzymes of this group were highest in liver. NAT2 was found in the large bowel but not in the liver or small bowel. Sulfotransferases (SULTs) were detected in liver but were absent in small intestine; two forms were present at moderate levels in the large intestine. Strong gender-dependent differences were observed for several enzymes in liver but not in gut. Colonic levels in germ-free animals differed from those in control animals (* indicates statistical significance) for GSTA1/2 (4.0*- and 5.0*-fold in males and females, respectively), GSTA4 (1.5*/1.9*-fold), GSTM1 (1.1/1.5*-fold), EPHX1 (3.5*/2.4*-fold), EPHX2 (1.4/2.1*-fold), SULT1B1 (0.4*/0.6*-fold), SULT1C2 (1.3/1.6*-fold), and NAT2 (1.4/1.5*-fold). Smaller effects were observed when rats were colonized with human, compared with rat, intestinal bacteria. Cecal enzyme levels in germ-free rats were changed similarly to those in colon. No effects were seen in small intestine. In liver, SULT1A1, SULT1C1, and SULT1C2 were elevated in germ-free animals of both genders (1.5- to 2.6-fold); hepatic EPHX2 was elevated 1.6-fold in females. In conclusion, intestinal microbiota can affect levels of xenobiotic-metabolizing enzymes in large intestine and liver, but the effects observed were moderate compared with tissue-dependent expression differences.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19282396     DOI: 10.1124/dmd.108.025916

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  31 in total

Review 1.  Xenobiotics: Interaction with the Intestinal Microflora.

Authors:  Kun Lu; Ridwan Mahbub; James G Fox
Journal:  ILAR J       Date:  2015

Review 2.  Gut microbiome interactions with drug metabolism, efficacy, and toxicity.

Authors:  Ian D Wilson; Jeremy K Nicholson
Journal:  Transl Res       Date:  2016-08-13       Impact factor: 7.012

3.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

Review 4.  Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.

Authors:  Alexander J Prokopienko; Thomas D Nolin
Journal:  Expert Rev Clin Pharmacol       Date:  2017-09-20       Impact factor: 5.045

Review 5.  The gastrointestinal microbiome: a malleable, third genome of mammals.

Authors:  Ian M Carroll; David W Threadgill; Deborah S Threadgill
Journal:  Mamm Genome       Date:  2009-07-21       Impact factor: 2.957

6.  Gender-Dependent Pharmacokinetics of Veratramine in Rats: In Vivo and In Vitro Evidence.

Authors:  Chunming Lyu; Yufeng Zhang; Wenbin Zhou; Shen Zhang; Fang Kou; Hai Wei; Ning Zhang; Zhong Zuo
Journal:  AAPS J       Date:  2016-01-20       Impact factor: 4.009

Review 7.  Understanding and modulating mammalian-microbial communication for improved human health.

Authors:  Sridhar Mani; Urs A Boelsterli; Matthew R Redinbo
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-10-23       Impact factor: 13.820

Review 8.  Uraemic syndrome of chronic kidney disease: altered remote sensing and signalling.

Authors:  Sanjay K Nigam; Kevin T Bush
Journal:  Nat Rev Nephrol       Date:  2019-05       Impact factor: 28.314

9.  Rationale for further medical and health research on high-potency sweeteners.

Authors:  Susan S Schiffman
Journal:  Chem Senses       Date:  2012-04-26       Impact factor: 3.160

Review 10.  Pharmacological Efficacy/Toxicity of Drugs: A Comprehensive Update About the Dynamic Interplay of Microbes.

Authors:  Juan Antonio Gimenez-Bastida; Lucia Martinez Carreras; Angela Moya-Pérez; José Moisés Laparra Llopis
Journal:  J Pharm Sci       Date:  2017-10-26       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.